Developer docs
API playgroundTry for free, no card

Search company profiles

23Strands

Full company profile

uuid0002shk

Namestring
23Strands
Legal namestring
23Strands
Websiteurl
23strands.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPyrmont, Australia
HQ citystring
Pyrmont
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
whole genome sequencing, precision medicine genomics, AI-driven genetic analysis, clinical genomics services, polygenic disease prediction
Industry6 codes
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLACABAA
Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAJAIAK
Public Health Genomics & Sequencing (WGS/Metagenomics) Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Clinical Genomics / Precision Medicine
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Genomic Testing Services
TypeSubscription Recurring
Description

Whole genome sequencing and AI-powered genomic analysis services for patients and clinicians. The company analyses entire genomes to provide personalised health insights across fertility, cardiovascular disease, and other conditions. Services are delivered through clinical partnerships and direct patient engagement.

23strands.com
2Geneve Health Platform Services
TypeSubscription Recurring
Description

Commercial precision medicine services for women's and reproductive health delivered through the wholly-owned subsidiary Geneve Health, encompassing genetic assessments with family planning specialists, ongoing care management through virtual clinics, and customisable benefit packages for payers and employers.

23strands.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Geneve
Description

Comprehensive women's and reproductive health program built on cutting-edge precision medicine, including personalised genetic insights, AI-powered clinical decision support, and whole-of-life care continuum from preconception through elderly care.

23strands.com
Core offering1 text field

23Strands provides whole genome sequencing (WGS) combined with proprietary AI and deep neural network analytics to deliver personalised, precision-medicine health insights for patients and clinicians. Its portfolio spans a core genomic platform and specialty programs including Fertility23 (unexplained infertility DNA analysis), Cardio23 (polygenic cardiovascular risk prediction), 23Plus (patient-facing WGS), the Biblioengine research tool, and Geneve Health — a wholly-owned subsidiary launched January 2026 focused on women's and reproductive health precision medicine delivered via a secure patient portal with EHR integration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Improved cardiovascular disease prediction accuracy by 21% compared to previous methods using deep neural networks analysing both indel variants and SNVs from whole genome sequences
+3 more records
Product overview1 text field

23Strands is a genomics healthcare technology company offering a core platform (23Strands Platform) for whole genome sequencing analysis combined with AI. The product portfolio includes specialty verticals: Fertility23 for fertility/infertility genetic analysis, Cardio23 for cardiovascular disease prediction, and Geneve Health (a wholly-owned subsidiary launched January 2026) for women's and reproductive precision medicine. Supporting products include 23Plus (patient-facing WGS) and the Biblioengine research tool. The platform integrates genomic data with clinical records and provides AI-powered analytics, connecting patients with multidisciplinary care pathways.

Product and service3 records
123Strands Platform
CategoryCore Genomics Platform
Description

Core genomic analysis platform that combines whole genome sequencing with AI to deliver comprehensive personalised health insights, integrated with clinical records and connected to multidisciplinary care pathways for patients and clinicians.

2Fertility23
CategorySpecialty Vertical - Fertility
Description

Specialty fertility product using DNA analysis to identify potential causes of unexplained infertility; provides precision analysis and recommendations for both patients and clinicians, analysing individual genetic variations that affect fertility outcomes.

3Geneve Health
CategorySpecialty Vertical - Women's & Reproductive Health
Description

Wholly-owned subsidiary delivering advanced genomic analytics tailored for fertility, pregnancy outcomes, and hormonal health, with AI-powered clinical decision support and a whole-of-life care continuum spanning preconception to elderly care through a secure patient portal with family-sharing.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeOthersAnnounced on2026-01-09
Description

Geneve Health Pty Ltd is a wholly 23Strands owned and dedicated entity, exclusively focused on advancing precision medicine in women's and reproductive health. Launched commercially in January 2026, Geneve delivers advanced genomic analytics tailored for fertility, pregnancy outcomes, and hormonal health, AI-powered clinical decision support, and a whole-of-life care continuum spanning preconception to elderly care.

2Monash University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-08
Description

23Strands partnered with Monash University (led by Professor Beverley Vollenhoven) and Virtus Health for a world-first AI IVF study. The collaboration integrates genomics, artificial intelligence, and clinical care to set a new global standard for personalised IVF medication dosing. The MRFF grant of $3 million funds the four-year research program.

23strands.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-08
Description

Virtus Health, a major IVF service provider and the first to develop AI embryo selection software, partnered with 23Strands for a world-first AI IVF study. The partnership aims to offer whole-genome sequencing and AI to augment reproductive decision-making and help patients achieve their dream of starting a family. Virtus Health CEO James Pyne endorsed the project.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-06-23
Description

23Strands and TRIAS signed a memorandum of understanding (MOU) to advance genomics in healthcare. The collaboration aims to: identify methods for medical diagnosis and treatment using genomics and clinical reports; identify standards, ethics, and governance for clinical genomic translation; develop a data pipeline for clinical genomic services including whole human genomics, variant calling, and outcome data analysis; identify and co-develop new research projects; collaborate on co-marketing efforts; plan team and training development; and explore international market opportunities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-09
Description

23Strands partnered with the UTS Australian Artificial Intelligence Institute (led by Professor Jie Lu) for a highly competitive Australian Research Council (ARC Linkage) Grant on applying AI in analysis, management, and clinical recommendation for personalised disease treatment. The project is split into three main areas: AI analysis of Whole Human Genome Sequencing data, intelligent computer-aided recommendations integrating medical records with genomics, and healthcare pathway optimisation. Total project funding exceeds $2.2 million over 3 years.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

23Strands conducted a joint research project with the Victor Chang Cardiac Research Institute (along with UTS and Sydney Heart Bank) to unveil genomic differences between peripartum cardiomyopathy (PPCM) and other forms of cardiomyopathy. The research used the Biblioengine prototype and AI to identify genes associated with PPCM.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

23Strands collaborated with the Sydney Heart Bank (along with UTS and Victor Chang Cardiac Research Institute) on a joint research project identifying genomic distinctions between peripartum cardiomyopathy and other forms of cardiomyopathy.

Strategic tierSupportingTypeTechnology or Integration
Description

23Strands partnered with Australian cybersecurity company Haventec on the eConsent for Genomics platform, supported by AustCyber. This decentralised platform enables confidential genomic testing consent and secure data storage. 23Strands plans to roll out this solution in the community for greater protection of sensitive genomic information.

Strategic tierSupportingTypeTechnology or Integration
Description

Oracle is described as a commercial healthcare informatics partner of 23Strands. The partnership is noted in the context of Oracle's acquisition of Cerner (a major EHR vendor) for $28 billion. 23Strands expressed excitement about future opportunities and innovations this acquisition would bring to Oracle and the 23Strands team.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

23Strands received Medical Research Future Funding to play an integral and leading role in researching the benefit of genomic medicine to Indigenous Australians. Professor Alex Brown from ANU leads a five-year collaboration to establish the National Indigenous Genomics Network, engaging Indigenous Australians in genetic research and healthcare in a culturally safe way.

11Industry Genomic Network Alliance (InGeNA)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

23Strands is a founding member of InGeNA, contributing to the development of the industry review 'Genomic Data in Australia,' which highlights the importance of data management in health and genomics and supports advancement within Australia's healthcare landscape.

23strands.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US clinical genomics company focused on whole genome sequencing-based tests for cancer and other diseases, with proprietary analytics pipelines. Comparable to 23Strands' deep WGS + AI interpretation stack.

TypeBroad incumbent
Description

Established US clinical genetics company spanning hereditary cancer, women's health, and pharmacogenomics with deep reimbursement infrastructure. A broad incumbent in the precision-medicine category where 23Strands is competing with focused specialty verticals.

3Sema4 (now GeneDx)
TypeBroad incumbent
Description

US-based clinical genomics and data platform offering hereditary disease, reproductive health, and oncology testing paired with AI-driven interpretation. Comparable as a broader incumbent offering clinical genomic interpretation at scale across similar use cases to 23Strands.

TypeDirect peer
Description

US clinical genetics company offering WGS- and panel-based testing across hereditary cancer, cardiovascular, and reproductive health, with employer/payer distribution. Overlaps directly with 23Strands' Fertility23 and Cardio23 verticals and its Geneve Health payer/employer model.

TypeBroad incumbent
Description

Consumer and clinical genomics company with large-scale genomic database, polygenic risk scores, and pharma collaborations. Comparable to 23Strands as a major player in consumer/clinical genomics and polygenic disease prediction, though at vastly greater scale.

TypeRegional player
Description

Australian-listed clinical genomics company offering hereditary cancer risk and polygenic risk tests across the Australian and Asian markets. Regional peer competing in the same domestic market as 23Strands with overlapping genomic risk prediction offerings.

TypeEmerging player
Description

Switzerland-based genomic data and analytics platform offering clinical interpretation, biobanking, and translational informatics. Comparable to 23Strands on the bioinformatics/clinical interpretation and data-pipeline layer, including their TRIAS MOU partner-type activities.

TypeDirect peer
Description

UK-based company that uses large-scale genomic and phenotypic data to build polygenic risk prediction models for common diseases. Directly comparable to 23Strands' deep-neural-network approach to cardiovascular polygenic prediction.

TypeDirect peer
Description

US clinical and consumer genomics laboratory offering whole genome and whole exome sequencing with clinical interpretation services. Directly comparable to 23Strands as a CLIA-style clinical WGS provider.

TypeDirect peer
Description

US-based clinical genomics company built around a whole genome sequencing platform with clinical-grade bioinformatics, partner integrations, and population health programs. Directly comparable to 23Strands in using WGS (rather than targeted panels) as the foundation for clinical insights.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

23Strands

Clinical Genomics / Precision Medicine23strands.com

23Strands firmographics

Firmographics
Name
23Strands
Legal name
23Strands
Website
https://23strands.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

23Strands industry classification

Industry
Product category
Clinical Genomics / Precision Medicine
NAICS
Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLACABAA
Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAJAIAK
Public Health Genomics & Sequencing (WGS/Metagenomics) Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

  • Whole genome sequencing
  • Precision medicine genomics
  • AI-driven genetic analysis
  • Clinical genomics services
  • Polygenic disease prediction

Where 23Strands is headquartered

Location

Headquarters

HQ city
Pyrmont
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

23Strands business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Genomic Testing Services: Whole genome sequencing and AI-powered genomic analysis services for patients and clinicians. The company analyses entire genomes to provide personalised health insights across fertility, cardiovascular disease, and other conditions. Services are delivered through clinical partnerships and direct patient engagement.
  2. Geneve Health Platform Services: Commercial precision medicine services for women's and reproductive health delivered through the wholly-owned subsidiary Geneve Health, encompassing genetic assessments with family planning specialists, ongoing care management through virtual clinics, and customisable benefit packages for payers and employers.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

23Strands product offering

Product offering

Core offering

23Strands provides whole genome sequencing (WGS) combined with proprietary AI and deep neural network analytics to deliver personalised, precision-medicine health insights for patients and clinicians. Its portfolio spans a core genomic platform and specialty programs including Fertility23 (unexplained infertility DNA analysis), Cardio23 (polygenic cardiovascular risk prediction), 23Plus (patient-facing WGS), the Biblioengine research tool, and Geneve Health — a wholly-owned subsidiary launched January 2026 focused on women's and reproductive health precision medicine delivered via a secure patient portal with EHR integration.

Product overview

23Strands is a genomics healthcare technology company offering a core platform (23Strands Platform) for whole genome sequencing analysis combined with AI. The product portfolio includes specialty verticals: Fertility23 for fertility/infertility genetic analysis, Cardio23 for cardiovascular disease prediction, and Geneve Health (a wholly-owned subsidiary launched January 2026) for women's and reproductive precision medicine. Supporting products include 23Plus (patient-facing WGS) and the Biblioengine research tool. The platform integrates genomic data with clinical records and provides AI-powered analytics, connecting patients with multidisciplinary care pathways.

Differentiator

Problem solved

Functional benefit

Brands

  • Geneve: Comprehensive women's and reproductive health program built on cutting-edge precision medicine, including personalised genetic insights, AI-powered clinical decision support, and whole-of-life care continuum from preconception through elderly care.

Products and services

  • 23Strands Platform Core genomic analysis platform that combines whole genome sequencing with AI to deliver comprehensive personalised health insights, integrated with clinical records and connected to multidisciplinary care pathways for patients and clinicians.
  • Fertility23 Specialty fertility product using DNA analysis to identify potential causes of unexplained infertility; provides precision analysis and recommendations for both patients and clinicians, analysing individual genetic variations that affect fertility outcomes.
  • Geneve Health Wholly-owned subsidiary delivering advanced genomic analytics tailored for fertility, pregnancy outcomes, and hormonal health, with AI-powered clinical decision support and a whole-of-life care continuum spanning preconception to elderly care through a secure patient portal with family-sharing.

Quantifiable outcome

  • Improved cardiovascular disease prediction accuracy by 21% compared to previous methods using deep neural networks analysing both indel variants and SNVs from whole genome sequences
  • +3 more outcomes

Companies that use 23Strands

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

23Strands technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature7 records

23Strands partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, major, minor and supporting.

  • Geneve Health Pty LtdcoreOthers · 9 January 2026Geneve Health Pty Ltd is a wholly 23Strands owned and dedicated entity, exclusively focused on advancing precision medicine in women's and reproductive health. Launched commercially in January 2026, Geneve delivers advanced genomic analytics tailored for fertility, pregnancy outcomes, and hormonal health, AI-powered clinical decision support, and a whole-of-life care continuum spanning preconception to elderly care.
  • Monash UniversitycoreStrategic or Co-development Partner · 8 December 202323Strands partnered with Monash University (led by Professor Beverley Vollenhoven) and Virtus Health for a world-first AI IVF study. The collaboration integrates genomics, artificial intelligence, and clinical care to set a new global standard for personalised IVF medication dosing. The MRFF grant of $3 million funds the four-year research program.
  • Virtus HealthcoreStrategic or Co-development Partner · 8 December 2023Virtus Health, a major IVF service provider and the first to develop AI embryo selection software, partnered with 23Strands for a world-first AI IVF study. The partnership aims to offer whole-genome sequencing and AI to augment reproductive decision-making and help patients achieve their dream of starting a family. Virtus Health CEO James Pyne endorsed the project.
  • TRIASmajorStrategic or Co-development Partner · 23 June 202323Strands and TRIAS signed a memorandum of understanding (MOU) to advance genomics in healthcare. The collaboration aims to: identify methods for medical diagnosis and treatment using genomics and clinical reports; identify standards, ethics, and governance for clinical genomic translation; develop a data pipeline for clinical genomic services including whole human genomics, variant calling, and outcome data analysis; identify and co-develop new research projects; collaborate on co-marketing efforts; plan team and training development; and explore international market opportunities.
  • University of Technology Sydney (UTS) / Australian Artificial Intelligence InstitutecoreStrategic or Co-development Partner · 9 May 202223Strands partnered with the UTS Australian Artificial Intelligence Institute (led by Professor Jie Lu) for a highly competitive Australian Research Council (ARC Linkage) Grant on applying AI in analysis, management, and clinical recommendation for personalised disease treatment. The project is split into three main areas: AI analysis of Whole Human Genome Sequencing data, intelligent computer-aided recommendations integrating medical records with genomics, and healthcare pathway optimisation. Total project funding exceeds $2.2 million over 3 years.
  • Victor Chang Cardiac Research InstituteminorStrategic or Co-development Partner23Strands conducted a joint research project with the Victor Chang Cardiac Research Institute (along with UTS and Sydney Heart Bank) to unveil genomic differences between peripartum cardiomyopathy (PPCM) and other forms of cardiomyopathy. The research used the Biblioengine prototype and AI to identify genes associated with PPCM.
  • Sydney Heart BankminorStrategic or Co-development Partner23Strands collaborated with the Sydney Heart Bank (along with UTS and Victor Chang Cardiac Research Institute) on a joint research project identifying genomic distinctions between peripartum cardiomyopathy and other forms of cardiomyopathy.
  • HaventecsupportingTechnology or Integration23Strands partnered with Australian cybersecurity company Haventec on the eConsent for Genomics platform, supported by AustCyber. This decentralised platform enables confidential genomic testing consent and secure data storage. 23Strands plans to roll out this solution in the community for greater protection of sensitive genomic information.
  • OraclesupportingTechnology or IntegrationOracle is described as a commercial healthcare informatics partner of 23Strands. The partnership is noted in the context of Oracle's acquisition of Cerner (a major EHR vendor) for $28 billion. 23Strands expressed excitement about future opportunities and innovations this acquisition would bring to Oracle and the 23Strands team.
  • Australian National University (ANU) / Professor Alex BrownmajorStrategic or Co-development Partner23Strands received Medical Research Future Funding to play an integral and leading role in researching the benefit of genomic medicine to Indigenous Australians. Professor Alex Brown from ANU leads a five-year collaboration to establish the National Indigenous Genomics Network, engaging Indigenous Australians in genetic research and healthcare in a culturally safe way.
  • Industry Genomic Network Alliance (InGeNA)supportingStrategic or Co-development Partner23Strands is a founding member of InGeNA, contributing to the development of the industry review 'Genomic Data in Australia,' which highlights the importance of data management in health and genomics and supports advancement within Australia's healthcare landscape.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

23Strands competitors and assessment

Company assessment

Direct peers

  • Personalis: US clinical genomics company focused on whole genome sequencing-based tests for cancer and other diseases, with proprietary analytics pipelines. Comparable to 23Strands' deep WGS + AI interpretation stack.
  • Color Genomics: US clinical genetics company offering WGS- and panel-based testing across hereditary cancer, cardiovascular, and reproductive health, with employer/payer distribution. Overlaps directly with 23Strands' Fertility23 and Cardio23 verticals and its Geneve Health payer/employer model.
  • Genomics plc: UK-based company that uses large-scale genomic and phenotypic data to build polygenic risk prediction models for common diseases. Directly comparable to 23Strands' deep-neural-network approach to cardiovascular polygenic prediction.
  • Gene by Gene: US clinical and consumer genomics laboratory offering whole genome and whole exome sequencing with clinical interpretation services. Directly comparable to 23Strands as a CLIA-style clinical WGS provider.
  • Helix: US-based clinical genomics company built around a whole genome sequencing platform with clinical-grade bioinformatics, partner integrations, and population health programs. Directly comparable to 23Strands in using WGS (rather than targeted panels) as the foundation for clinical insights.

Broad incumbents

  • Myriad Genetics: Established US clinical genetics company spanning hereditary cancer, women's health, and pharmacogenomics with deep reimbursement infrastructure. A broad incumbent in the precision-medicine category where 23Strands is competing with focused specialty verticals.
  • Sema4 (now GeneDx): US-based clinical genomics and data platform offering hereditary disease, reproductive health, and oncology testing paired with AI-driven interpretation. Comparable as a broader incumbent offering clinical genomic interpretation at scale across similar use cases to 23Strands.
  • 23andMe: Consumer and clinical genomics company with large-scale genomic database, polygenic risk scores, and pharma collaborations. Comparable to 23Strands as a major player in consumer/clinical genomics and polygenic disease prediction, though at vastly greater scale.

Regional players

  • Genetic Technologies (GTG): Australian-listed clinical genomics company offering hereditary cancer risk and polygenic risk tests across the Australian and Asian markets. Regional peer competing in the same domestic market as 23Strands with overlapping genomic risk prediction offerings.

Emerging players

  • BC Platforms: Switzerland-based genomic data and analytics platform offering clinical interpretation, biobanking, and translational informatics. Comparable to 23Strands on the bioinformatics/clinical interpretation and data-pipeline layer, including their TRIAS MOU partner-type activities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

23Strands social profiles

Digital presence

23Strands financial estimates

Financial estimate

Revenue estimate

Valuation estimate

23Strands leadership team

Management profile

Number of profiles

Profiles3 records

23Strands subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

23Strands funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

23Strands M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 23Strands

What does 23Strands do?

23Strands provides whole genome sequencing (WGS) combined with proprietary AI and deep neural network analytics to deliver personalised, precision-medicine health insights for patients and clinicians. Its portfolio spans a core genomic platform and specialty programs including Fertility23 (unexplained infertility DNA analysis), Cardio23 (polygenic cardiovascular risk prediction), 23Plus (patient-facing WGS), the Biblioengine research tool, and Geneve Health — a wholly-owned subsidiary launched January 2026 focused on women's and reproductive health precision medicine delivered via a secure patient portal with EHR integration.

Is 23Strands a public or private company?

23Strands is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was 23Strands founded?

23Strands was founded in 2019. It employs 11 to 50 people.

Where is 23Strands based?

23Strands is headquartered in Pyrmont, Australia, in the Oceania region.

How does 23Strands make money?

Two revenue lines are on record. Genomic Testing Services are the primary driver. The others are geneve Health Platform Services.

Who are 23Strands's main competitors?

Direct peers on record are Personalis, Color Genomics, Genomics plc, Gene by Gene and Helix. Broad incumbents are Myriad Genetics, Sema4 (now GeneDx) and 23andMe. Genetic Technologies (GTG) is listed as a regional player. BC Platforms is listed as an emerging player.

Does 23Strands have an API?

No public API is recorded for 23Strands.

What industry is 23Strands in?

23Strands's product category is Clinical Genomics / Precision Medicine. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals